PE20150465A1 - Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 - Google Patents
Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2Info
- Publication number
- PE20150465A1 PE20150465A1 PE2015000275A PE2015000275A PE20150465A1 PE 20150465 A1 PE20150465 A1 PE 20150465A1 PE 2015000275 A PE2015000275 A PE 2015000275A PE 2015000275 A PE2015000275 A PE 2015000275A PE 20150465 A1 PE20150465 A1 PE 20150465A1
- Authority
- PE
- Peru
- Prior art keywords
- beta
- compound
- adrene
- salts
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMA CRISTALINA DE LA SAL DE ACETATO DEL COMPUESTO (R)-7-(2-(1-(4-BUTOXI-FENIL)-2-METIL-PROPAN-2-IL-AMINO)-1-HIDROXI-ETIL)-5-HIDROXI-BENZO-[d]-TIAZOL-2(3H)-ONA DE FORMULA (I) CUYO PATRON DE DIFRACCION EN POLVO DE RAYOS X EXPRESADOS EN ANGULOS 2-THETA COMPRENDE TRES PICOS QUE TIENEN VALORES SELECCIONADOS DE 8.8 � 0.2�, 16.4 � 0.2� Y 20.8 � 0.2�, CUANDO SE MIDEN UTILIZANDO RADIACION DE CuK alfa. TAMBIEN SE REFIERE A UN PROCESO PARA SU ELABORACION Y A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN AGONISTA DEL ADRENO-RECEPTOR BETA-2 SIENDO UTIL PARA EL TRATAMIENTO DE DISTROFIA MUSCULAR, ATROFIA RELACIONADA CON DESUSO, CAQUEXIA O SARCOPENIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ23912 | 2012-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150465A1 true PE20150465A1 (es) | 2015-04-22 |
Family
ID=53386469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000275A PE20150465A1 (es) | 2012-08-30 | 2013-08-29 | Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP3243817A1 (es) |
| KR (1) | KR20150047586A (es) |
| CN (2) | CN104736525B (es) |
| BR (1) | BR112015004127A2 (es) |
| CA (1) | CA2882877A1 (es) |
| CL (1) | CL2015000461A1 (es) |
| CY (1) | CY1120225T1 (es) |
| DK (1) | DK2890687T3 (es) |
| EA (1) | EA029946B1 (es) |
| ES (1) | ES2642003T3 (es) |
| HK (1) | HK1206015A1 (es) |
| HR (1) | HRP20171362T1 (es) |
| HU (1) | HUE033655T2 (es) |
| IL (1) | IL237382A0 (es) |
| LT (1) | LT2890687T (es) |
| MA (1) | MA37872A1 (es) |
| MX (1) | MX351741B (es) |
| MY (1) | MY169038A (es) |
| NZ (1) | NZ705319A (es) |
| PE (1) | PE20150465A1 (es) |
| PL (1) | PL2890687T3 (es) |
| PT (1) | PT2890687T (es) |
| SA (1) | SA515360076B1 (es) |
| SG (2) | SG11201501293PA (es) |
| SI (1) | SI2890687T1 (es) |
| TN (1) | TN2015000058A1 (es) |
| WO (1) | WO2014033654A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3192B1 (ar) * | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| JP2007537187A (ja) | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物 |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| JO3192B1 (ar) * | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| SG11201505544RA (en) * | 2013-02-28 | 2015-09-29 | Novartis Ag | Formulation comprising benzothiazolone compound |
-
2013
- 2013-08-29 EA EA201590452A patent/EA029946B1/ru not_active IP Right Cessation
- 2013-08-29 CN CN201380055093.1A patent/CN104736525B/zh not_active Expired - Fee Related
- 2013-08-29 MA MA37872A patent/MA37872A1/fr unknown
- 2013-08-29 PL PL13812075T patent/PL2890687T3/pl unknown
- 2013-08-29 EP EP17171708.5A patent/EP3243817A1/en not_active Withdrawn
- 2013-08-29 WO PCT/IB2013/058109 patent/WO2014033654A1/en active Application Filing
- 2013-08-29 CA CA2882877A patent/CA2882877A1/en not_active Abandoned
- 2013-08-29 CN CN201610537241.9A patent/CN106146428A/zh active Pending
- 2013-08-29 SI SI201330750T patent/SI2890687T1/sl unknown
- 2013-08-29 EP EP13812075.3A patent/EP2890687B1/en active Active
- 2013-08-29 HU HUE13812075A patent/HUE033655T2/en unknown
- 2013-08-29 PE PE2015000275A patent/PE20150465A1/es not_active Application Discontinuation
- 2013-08-29 DK DK13812075.3T patent/DK2890687T3/en active
- 2013-08-29 MY MYPI2015000453A patent/MY169038A/en unknown
- 2013-08-29 PT PT138120753T patent/PT2890687T/pt unknown
- 2013-08-29 ES ES13812075.3T patent/ES2642003T3/es active Active
- 2013-08-29 KR KR1020157007573A patent/KR20150047586A/ko not_active Application Discontinuation
- 2013-08-29 SG SG11201501293PA patent/SG11201501293PA/en unknown
- 2013-08-29 LT LTEP13812075.3T patent/LT2890687T/lt unknown
- 2013-08-29 MX MX2015002656A patent/MX351741B/es active IP Right Grant
- 2013-08-29 BR BR112015004127A patent/BR112015004127A2/pt not_active Application Discontinuation
- 2013-08-29 NZ NZ705319A patent/NZ705319A/en not_active IP Right Cessation
- 2013-08-29 SG SG10201704377PA patent/SG10201704377PA/en unknown
-
2015
- 2015-02-20 TN TNP2015000058A patent/TN2015000058A1/fr unknown
- 2015-02-23 IL IL237382A patent/IL237382A0/en unknown
- 2015-02-25 CL CL2015000461A patent/CL2015000461A1/es unknown
- 2015-02-26 SA SA515360076A patent/SA515360076B1/ar unknown
- 2015-07-08 HK HK15106522.7A patent/HK1206015A1/xx not_active IP Right Cessation
-
2017
- 2017-09-11 HR HRP20171362TT patent/HRP20171362T1/hr unknown
- 2017-09-13 CY CY20171100967T patent/CY1120225T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2890687A1 (en) | 2015-07-08 |
| IL237382A0 (en) | 2015-04-30 |
| MX2015002656A (es) | 2015-05-20 |
| EA029946B1 (ru) | 2018-06-29 |
| SG10201704377PA (en) | 2017-06-29 |
| HUE033655T2 (en) | 2017-12-28 |
| TN2015000058A1 (en) | 2016-06-29 |
| CN104736525B (zh) | 2016-08-24 |
| HRP20171362T1 (hr) | 2017-11-03 |
| SA515360076B1 (ar) | 2016-03-20 |
| CA2882877A1 (en) | 2014-03-06 |
| MA37872A1 (fr) | 2018-07-31 |
| MX351741B (es) | 2017-10-26 |
| HK1206015A1 (en) | 2015-12-31 |
| CN106146428A (zh) | 2016-11-23 |
| PT2890687T (pt) | 2017-10-05 |
| EA201590452A1 (ru) | 2015-07-30 |
| EP2890687B1 (en) | 2017-06-28 |
| NZ705319A (en) | 2018-05-25 |
| SI2890687T1 (sl) | 2017-10-30 |
| BR112015004127A2 (pt) | 2017-07-04 |
| DK2890687T3 (en) | 2017-10-09 |
| LT2890687T (lt) | 2017-09-11 |
| PL2890687T3 (pl) | 2017-11-30 |
| CY1120225T1 (el) | 2018-12-12 |
| KR20150047586A (ko) | 2015-05-04 |
| WO2014033654A1 (en) | 2014-03-06 |
| MY169038A (en) | 2019-02-07 |
| EP3243817A1 (en) | 2017-11-15 |
| CL2015000461A1 (es) | 2015-05-04 |
| SG11201501293PA (en) | 2015-03-30 |
| CN104736525A (zh) | 2015-06-24 |
| ES2642003T3 (es) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| BR112014016287A2 (pt) | composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma | |
| CR20160099A (es) | Formulación de inhibidores de la syk | |
| BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
| BR112015004547A2 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
| EP2649060A4 (en) | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND THEIR SALTS | |
| DK2827710T3 (da) | Doseringsskema for echinocandin-klasse-forbindelser | |
| CL2014002756A1 (es) | Compuestos derivados de 1,4-benzotiazepina; composición farmacéutica que lo comprende; uso para tratar afecciones relacionadas con función anormal de receptores de rianodina; y método de preparación del compuesto. | |
| HU1000069D0 (en) | New salts for the preparation of pharmaceutical composition | |
| BR112015007310A2 (pt) | compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica | |
| AR107548A1 (es) | Forma cristalina a de agonista de tlr7, su proceso de preparación y uso | |
| CR20150245A (es) | Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer | |
| BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia | |
| PT3541814T (pt) | Compostos de amino-naft[1,2-d]imidazol-5-ona 2-substituída ou seus sais farmaceuticamente aceitáveis | |
| BR112012029226A2 (pt) | processo para a preparação de um composto quiral, composto quiral cristalino, sal de hcl do composto quiral cristalino, composto quiral e uso do composto | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| EP2736905A4 (en) | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | |
| CR20140325A (es) | Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- | |
| MX2015012318A (es) | Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. | |
| HK1210969A1 (en) | Substituted heterocyclic compounds for disease treatment | |
| BR112014001425A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo | |
| PE20150465A1 (es) | Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 | |
| BR112015012877A2 (pt) | composto de fórmula, composição farmacêutica, uso do composto e método para o tratamento do câncer | |
| PH12015501701A1 (en) | Formulation comprising benzothiazolone compound | |
| SG11201405152TA (en) | Isoindolo[2,1-a]quinazoline derivatives for stabilization of organic materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |